Polypharmacy in Schizophrenia: Understanding Its Drivers and Potential Impact

This beginner-level educational article provides an overview of the prevalence, clinical drivers, system-level contributors, and potential impact of polypharmacy in schizophrenia management. It examines why polypharmacy persists in real-world practice despite limited evidence of efficacy, highlighting the role of illness severity, treatment response, and fragmented care transitions. The article concludes by emphasizing the need for guideline-concordant treatment, careful reassessment of ongoing medication needs, and a nuanced understanding of the chronic, unremitting nature of schizophrenia in informing treatment decisions.

Introduction

Schizophrenia is a chronic, serious psychiatric disorder characterized by positive, negative, and cognitive symptoms that can contribute to functional disability.¹ Long-term pharmacologic treatment is a key component of disease management to help with symptom control; however, treatment outcomes in routine clinical practice remain inconsistent, and as a result, alternative treatment strategies may be employed in the real world in an effort to improve outcomes.¹ Importantly, schizophrenia is a chronic, unremitting condition in which complete symptom resolution is rarely achieved; persistent symptoms therefore reflect the nature of the illness.^1,2 Polypharmacy, broadly defined as the concurrent use of multiple medications, is observed in the management of schizophrenia and may arise from efforts to address the multidimensional nature of the disease.³ This may include the use of multiple psychotropic agents, referred to as psychotropic polypharmacy.³ Clinicians may also prescribe antipsychotics to manage symptoms of schizophrenia.⁴ The use of multiple antipsychotics is known as antipsychotic polypharmacy.^1,4-7 Clinical practice guidelines—including those from the American Psychiatric Association (APA), and the National Institute for Health and Care Excellence (NICE)—cite limited and varying evidence for the use of multiple antipsychotics in the treatment of schizophrenia.^1,5 However, clinicians may encounter complex clinical presentations that may not be fully addressed by published treatment guidelines, thus contributing to continued real-world use of polypharmacy in selected patients.¹

Prevalence and Patterns of Polypharmacy in Schizophrenia

Polypharmacy is thought to occur in schizophrenia across several geographic regions and care settings. Systematic reviews and meta-analyses indicate that antipsychotic polypharmacy occurred in approximately 10% to 40% of patients with schizophrenia.^4,6,7 Real-world evidence in the United States suggests that nearly 30% of patients treated with oral antipsychotics received concurrent treatment with an additional antipsychotic during routine care, and up to 50% of patients switched their medication.⁷ Polypharmacy extends beyond antipsychotic combinations alone and includes antidepressants, mood stabilizers, sedative-hypnotics, and medications used to manage adverse events (AEs).^3,5,8 Discharge prescribing data demonstrate that polypharmacy can be present at transitions from inpatient care, highlighting the persistence of combination regimens in routine clinical practice.⁹ Together, these prevalence patterns suggest that a complex set of clinical and system-level factors shapes the persistence of polypharmacy in schizophrenia.

Clinical Drivers of Polypharmacy

Clinical factors appear to be the primary drivers of polypharmacy in schizophrenia. Based on a meta-analysis of individual patient data from 16 short-term (4-6 weeks) randomized controlled trials of 7 different antipsychotics, approximately 20% of patients showed 0% improvement on symptom-severity scales; approximately 43% of patients showed <25% improvement; and about 67% of patients showed <50% improvement.¹⁰

Because of the variability in patient response to antipsychotic medication due to individual patient factors, clinicians may employ combination therapy when managing severe, high-risk, or unstable presentations.⁶ Patients with comorbid mood symptoms, anxiety, aggression, or sleep disturbances may also be more likely to receive adjunctive psychotropic medications.⁸

AEs represent another important contributor to polypharmacy, as clinicians may introduce additional medications to mitigate treatment-associated side effects rather than consider alternative treatment strategies that might include discontinuing or replacing the primary agent.^1,4 Over time, compensatory prescribing to manage these and other common AEs may increase the cumulative medication burden.^1,11

System-Level Contributors to Polypharmacy

Key clinical practice guidelines, including those from the APA, mention antipsychotic monotherapy but provide limited operational details for managing responses, symptoms, or tolerability challenges.^5,12 Current APA practice guidelines recommend that patients with schizophrenia be treated with an antipsychotic medication and be monitored for effectiveness and side effects.

Factors that could affect treatment response, such as concomitant substance abuse, rapid medication metabolism, poor medication absorption, interactions with other medications, and other effects on drug metabolism (eg, smoking) that could affect blood levels of medication, as well as potential adherence issues, should also be considered.⁵

Still, clinicians frequently encounter clinical scenarios that may not be fully addressed by guideline algorithms, necessitating individualized decision-making.¹ The challenge of addressing symptoms, especially for patients with complex presentations, is ranked as an important reason for antipsychotic polypharmacy, which reinforces the reliance on clinician experience and not just consideration of standardized pathways.⁴

Fragmented care transitions introduce additional challenges. Transitions between care settings are considered key points of vulnerability for medication continuity, in part because they require coordination among multiple clinical disciplines. Evidence from health systems indicates that medication reconciliation processes may be suboptimal at these transitions, potentially contributing to the persistence of multi-medication regimens.^13,14

Considerations of Polypharmacy

Polypharmacy in schizophrenia has been associated with meaningful clinical, safety, and economic considerations. Observational studies show that polypharmacy can be associated with higher total daily antipsychotic doses compared with monotherapy, and exposure to multiple treatments may be linked to an increased risk of adverse events and drug-drug interactions.⁴ Modeling studies suggest that when multiple antipsychotics with the same receptor targets are combined, this could lead to receptor occupancy levels exceeding the typical therapeutic window.¹⁵

Polypharmacy has also been associated with poorer medication adherence and persistence, which may impact relapse prevention and long-term functional recovery.^4,8 Multi-medication regimens increase treatment burden and may contribute to discontinuation, inconsistent use, or disengagement from care. From a health-system perspective, polypharmacy contributes to the economic burden of schizophrenia. Real-world US analyses demonstrate that patients receiving combination therapy incur higher annual medical costs, primarily due to increased medication expenditures.⁷

Although some cohort studies suggest reduced rehospitalization with specific multi-medication strategies in narrowly defined populations, findings remain inconsistent due to a lack of evidence from high-quality studies. Importantly, antipsychotic polypharmacy has not demonstrated a consistent benefit over antipsychotic monotherapy and may increase treatment complexity without a clear functional advantage for many patients.^4,12

Routine Medication Assessment & Deprescribing Strategies

Although polypharmacy is common, strategies exist to help tailor treatments to patients’ ongoing needs. The APA recommends that the physician regularly review the ongoing benefits and side effects of antipsychotic medications with the patient—and, if appropriate, their family—to determine whether the medication is still meeting the patient’s treatment goals or if adjustments are necessary.¹⁶

To help address the issue of polypharmacy and considerations for deprescribing, the American Society of Clinical Psychopharmacology published a consensus statement with strategies to review periodically and, if indicated through careful evaluation, discontinue psychotropic agents that may no longer benefit the patient.¹⁷

General principles of deprescribing include regularly assessing all psychotropic medicines at least once annually, including a collaborative risk-benefit analysis with patients.¹⁷

The practitioner should take into account the patient's cultural values and goals and ensure that the patient has a support network, which could include referring the patient for psychotherapy during the transition.¹⁷ 

This consensus also suggests specific strategies and considerations for deprescribing.¹⁷

Conclusion

Although its evidentiary support from large randomized controlled trials remains limited or unclear, polypharmacy in schizophrenia is observed in routine clinical practice. Antipsychotic polypharmacy represents a more specific subset of the broader concept of psychotropic polypharmacy, which encompasses the use of multiple psychiatric medications to address the diverse and often overlapping symptom domains of schizophrenia, including mood, anxiety, and sleep disturbances. Polypharmacy reflects the intersection of illness severity, treatment response, and reliance on individualized clinical judgment. While combination treatment regimens occur, they have been associated with increased AEs, reduced adherence, and higher health care costs, yet lack well-established evidence of their use. Improving schizophrenia care will require continued emphasis on careful reassessment of ongoing medication needs and a nuanced understanding of when the clinical benefits of polypharmacy may outweigh the potential risks. The persistent reliance on polypharmacy also underscores important unmet needs in the schizophrenia disease journey, as a substantial proportion of patients continue to experience symptoms and functional impairment that reflect the chronic nature of the illness. This limitation underscores the need for treatment strategies that can comprehensively address schizophrenia symptoms while considering the cumulative treatment burden.

References

1. Lähteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273–1284.
2. Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, Secher RG, Thorup AAE, Mors O, Nordentoft M. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017;182:42–48.
3. Govaerts J, Boeyckens J, Lammens A, et al. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital. Ther Adv Psychopharmacol. 2021;11:20451253211000610. doi: 10.1177/20451253211000610.
4. Pae CU. Antipsychotic polypharmacy in treatment of schizophrenia; should or should not? Chonnam Med J. 2020;56(3):157–165.
5. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868-872.
6. Højlund M, Rohde C, Gasse C, et al. Antipsychotic polypharmacy in patients with schizophrenia between 1999 and 2024 in Denmark: prevalence, time trends, and combinations. Eur Neuropsychopharmacol. 2025;100:4–12.
7. Martin A, Bessonova L, Hughes R, et al. Systematic review of real-world treatment patterns of oral antipsychotics and associated economic burden in patients with schizophrenia in the United States. Adv Ther. 2022;39(9):3933–3956.
8. Kamei H. Polypharmacy management of antipsychotics in patients with schizophrenia. Medicina (Kaunas). 2022;58(11):1584.
9. Hashimoto N, Yasui-Furukori N, Hasegawa N, et al. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project. Asian J Psychiatr. 2021;63:102744.
10. Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophr Bull. 2019;45(3):639-646.
11. Abou-Setta AM, Mousavi SS, Spooner C, et al. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Comparative Effectiveness Review No. 63. Rockville, MD: Agency for Healthcare Research and Quality; August 2012.
12. Taylor DM, Barnes TRE, Young AH. Chapter 1: Schizophrenia and related psychoses. In: The Maudsley Prescribing Guidelines in Psychiatry. 15th ed. John Wiley & Sons Ltd; 2025.
13. Kern LM, Bynum JPW, Pincus HA. Care fragmentation, care continuity, and care coordination-how they differ and why it matters. JAMA Intern Med. 2024;184(3):236–237.
14. Wang J, Shen JY, Conwell Y, et al. Implementation considerations of deprescribing interventions: a scoping review. J Intern Med. 2024;295(4):436–507.
15. Spangemacher M, Schmitz CN, Cumming P, et al. The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy. Transl Psychiatry. 2025;15:348. doi:10.1038/s41398-025-03582-2.
16. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 3rd Edition. American Psychiatric Publishing; 2021.
17. Goldberg JF, McIntyre RS, Swartz HA, et al. Recommendations for the deprescribing of psychotropic medications: a consensus statement from the American Society of Clinical Psychopharmacology Task Force. JAMA Netw Open. 2026;9(2):e260043. doi:10.1001/jamanetworkopen.2026.0043

© 2026 Bristol-Myers Squibb Company
NS-US-2600083 08/26